Latest treatment for high blood pressure renal artery cried

Latest treatment for high blood pressure renal artery cried

The Minister of Health and Population, Dr. Fouad Al Nawawi and the Governor of Cairo, Dr. Abdel Kawi Khalifa Medical Association, Dr. Khairy Abdel Dayem yesterday Annual International Conference of the 39 of the Egyptian Society of Cardiology and Dr. Ashraf Badawi, Consultant Cardiologist Rapporteur of the Conference that the Conference discussed over the past two days, several new research, including Showing the first case to treat high blood pressure by Ki-artery kidneys as the first way to treat high blood pressure drug-resistant through the catheter interventional and benefits of this treatment in patients who take more than three types of drugs to treat pressure was conducted several research on this method proved successful in control of high pressure instead of drugs at a rate of more than 30 degrees within 6 months of the process of ironing and the process of ironing by the introduction of a catheter to the renal artery through which to send shock waves at frequencies high so that the ends of nerves in the renal artery directly and takes less than half-hour topical anesthesia and sedation, which do not cause pain to the patient which is a great advancement in the treatment of blood pressure, which causes the death of many patients each year.

Dr. Ashraf and indicates that there are other topics are discussed in the expansion of a catheter through the coronary arteries, artery of the hand and this method is safe.

It is known that the usual way to enter the catheter is through the femoral artery, and this requires that the patient stays after the catheter to remain lying on the bed and bent his leg for the duration of 6:12 hours The new method, which is represented in the entry of the catheter through the artery of the hand the patient can be out of the hospital two hours after the conduct that is on his feet without any problems and return to work the next day and this method is used for the expansion of the coronary arteries and the installation of struts.

There are other research presented at the conference for new types of pharmacological stents, which is characterized by that the patient does not need to continue on anti-platelets for more than 6 months.

It is known that the traditional pharmaceutical stents require the patient to continue to engage in anti-platelet drugs for more than a year hence, when less than this period, less complications of medications.